Latest revenue
$182.2M
as of 2026-03-31
Latest net income
$5.1M
as of 2026-03-31
Net margin
2.8%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.15B
- Enterprise value
- $1.15B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $24.91
- 52-wk low
- $9.30
- Beta
- —
- Shares out
- 46.8M
5-year trend
What this company does
Table of Contents ITEM 1. BUSINESS Overview Avanos Medical, Inc. is a medical technology company focused on delivering clinically superior medical device solutions that help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today’s most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. Unless the context indicates otherwise, the…
AI summary unavailable — showing raw filing excerpt
Generated from AVNS's filing dated 2026-02-24
Key risks
Table of Contents ITEM 1A. RISK FACTORS Our business faces many risks and uncertainties. Any of the risks discussed below, as well as factors described in other places in this Annual Report on Form 10-K, or in our other filings with the SEC, could materially adversely affect our business, consolidated financial position, results of operations or cash flows. In addition, these items could cause our future results to differ from our recent results, from our anticipated future results and from those in any of our forward-looking statements. These risks are not the only ones we face. Other risks that we do not presently know about or that we presently believe are not material could also…
AI summary unavailable — showing raw filing excerpt
Generated from AVNS's filing dated 2026-02-24
Profitability
Gross margin
50.5%
9.0%Operating margin
-8.8%
84.7%Net margin
-10.4%
81.8%Return on equity
-9.4%
70.5%Return on assets
-6.8%
80.0%Leverage
Debt / equity
0.38×
671.8%Long-term debt / equity
0.12×
14.5%Debt / assets
27.5%
486.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $182.2M | +8.8% | $5.1M | -22.7% | 2.8% |
Q4 2025 2025-12-31 | $180.9M | +0.7% | $-7.9M | +98.0% | -4.4% |
Q3 2025 2025-09-30 | $177.8M | +4.3% | $-1.4M | -132.6% | -0.8% |
Q2 2025 2025-06-30 | $175.0M | +1.9% | $-70.2M | -7900.0% | -40.1% |
Q1 2025 2025-03-31 | $167.5M | +0.8% | $6.6M | +833.3% | 3.9% |
Q4 2024 2024-12-31 | $179.6M | — | $-396.4M | — | -220.7% |
Q3 2024 2024-09-30 | $170.4M | -0.5% | $4.3M | +216.2% | 2.5% |
Q2 2024 2024-06-30 | $171.7M | +1.4% | $900.0K | +101.3% | 0.5% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on AVNS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$659.3K
Insider selling
$165.0K
Net activity
+$494.3K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AVNS
Institutional value
$264.0M
Total shares held
21.4M
Distinct holders
161
-108 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6.8M | $95.9M | +92.8K (+1.4%) | Added |
| 2 | DIMENSIONAL FUND ADVISORS LP | 2.1M | $28.8M | -105.2K (-4.9%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $27.6M | — | New |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.2M | $17.4M | — | New |
| 5 | CLARK ESTATES INC/NY | 845.0K | $11.8M | -43.9K (-4.9%) | Trimmed |
| 6 | DIAMOND HILL CAPITAL MANAGEMENT INC | 573.9K | $8.0M | +64.2K (+12.6%) | Added |
| 7 | ROYCE & ASSOCIATES LP | 513.7K | $7.2M | +453.0K (+746.3%) | Added |
| 8 | Bank of New York Mellon Corp | 304.7K | $4.3M | -1.4K (-0.4%) | Trimmed |
| 9 | VANGUARD FIDUCIARY TRUST CO | 302.5K | $4.2M | — | New |
| 10 | PRINCIPAL FINANCIAL GROUP INC | 286.1K | $4.0M | -6.7K (-2.3%) | Trimmed |
| 11 | Allianz Asset Management GmbH | 265.6K | $3.7M | +124.2K (+87.9%) | Added |
| 12 | JPMORGAN CHASE & CO | 251.2K | $3.4M | -22.6K (-8.2%) | Trimmed |
| 13 | Invesco Ltd. | 211.1K | $3.0M | -12.2K (-5.5%) | Trimmed |
| 14 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 210.2K | $2.9M | +6.9K (+3.4%) | Added |
| 15 | JANE STREET GROUP, LLC | 199.2K | $2.8M | +179.9K (+932.3%) | Added |
| 16 | FRANKLIN RESOURCES INC | 189.0K | $2.6M | +113.1K (+149.2%) | Added |
| 17 | MARTINGALE ASSET MANAGEMENT L P | 180.4K | $2.5M | +22.4K (+14.2%) | Added |
| 18 | SEI INVESTMENTS CO | 167.9K | $2.4M | +92.1K (+121.3%) | Added |
| 19 | Public Sector Pension Investment Board | 166.1K | $2.3M | +5.2K (+3.2%) | Added |
| 20 | KESTREL INVESTMENT MANAGEMENT CORP | 139.8K | $2.0M | -1.2K (-0.9%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AVNS's latest filing finishes processing.